HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

486.200

+3.8440.80%

Number of Gainers:19

Number of Losers:8

Number of Flat:6

PE:- -

High:489.931

Open:482.072

Low:481.405

Close:482.357

Volume:30.65M

Turnover:739.27M

Market Cap:309.12B

Float Cap:274.68B

Loading ...

Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion

Genfleet-B Repurchases 75,000 Shares for HK$1.96 Million on September 9

HBM Holdings' Strategic Partner Secures $225M Series A, Launches Operations

HBM Partner Solstice Oncology Launches Phase 2 Trial of Porustobart in Neoadjuvant MSS Stage II-III Colon Cancer

Harbour Biomed Partner, Solstice Oncology, Announces $225 Million Series a Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

THOMSON REUTERS

Hbm Holdings - Solstice Oncology Launches $225 Mln Series a Financing Round

THOMSON REUTERS

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation at HKD 20.82-21.38

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal

BOC International sees pharma sector earnings recovery as industry enters a reversal cycle

HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth

HK-Listed HBM Climbs on Initiating Next Phase of Asthma Drug Study

Hong Kong Stock Market Movers: HBM Holdings-B (02142) Climbs Over 4% in Morning Session After Positive Asthma Trial Results and Stock Connect Inclusion

Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug

How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data

TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase

HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III

Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call

HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378

Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/BK1574/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":486.20044,"timestamp":1789616129890,"preClose":482.35672,"halted":0,"volume":30652011,"delay":0,"changeRate":0.007969,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":3.843719,"latestTime":"09-17 11:35:30","open":482.07187,"high":489.93134,"low":481.40475,"amount":739268358,"amplitude":0.017677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789617600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":3.604829,"peRate":160.310337,"turnoverRate":0.001166,"increases":19,"decrements":8,"flats":5,"marketCap":309120026320,"floatMarketCap":274679219272},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.93134,"amplitude":0.017677,"preClose":482.35672,"low":481.40475,"pbRate":"3.604829","latestPrice":486.20044,"volume":30652011,"delay":0,"open":482.07187,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.758,"twentyDayClose":517.015,"sixtyDayClose":440.071,"secType":"PLATE","market":"HK","turnoverRate":0.001166,"peRate":160.310337,"marketCap":309120026320,"floatMarketCap":274679219272,"timestamp":1789616129890,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":19,"down":8,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1113083232","title":"Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1113083232","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113083232?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:18","pubTimestamp":1788956296,"startTime":"0","endTime":"0","summary":"Everest Medicines (01952) has announced the signing of a strategic cooperation framework agreement with Hissen on September 9, 2026, under which both parties have agreed to establish a framework for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179497303","title":"Genfleet-B Repurchases 75,000 Shares for HK$1.96 Million on September 9","url":"https://stock-news.laohu8.com/highlight/detail?id=1179497303","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179497303?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:14","pubTimestamp":1788956052,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced that on September 9, 2026, the company spent HK$1.9608 million to repurchase 75,000 shares.The buyback transaction reflects the company's ongoing capital management...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","02595","159938","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173908290","title":"HBM Holdings' Strategic Partner Secures $225M Series A, Launches Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=1173908290","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173908290?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:18","pubTimestamp":1788952700,"startTime":"0","endTime":"0","summary":"HBM Holdings (02142) has announced that its partner company Solstice Oncology (Solstice) has successfully completed a $225 million Series A funding round and officially commenced operations. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587460","title":"HBM Partner Solstice Oncology Launches Phase 2 Trial of Porustobart in Neoadjuvant MSS Stage II-III Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587460","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587460?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:15","pubTimestamp":1788952514,"startTime":"0","endTime":"0","summary":"HBM partner Solstice Oncology launches Phase 2 trial of porustobart in neoadjuvant MSS stage II-III colon cancerHBM Holdings’ partner Solstice Oncology launched with a USD 225 million Series A to adva","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL71K3Mm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666163587","title":"Harbour Biomed Partner, Solstice Oncology, Announces $225 Million Series a Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666163587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666163587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:12","pubTimestamp":1788952368,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUAC6DRXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666976587","title":"Hbm Holdings - Solstice Oncology Launches $225 Mln Series a Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2666976587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666976587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952256,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582914","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation at HKD 20.82-21.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582914","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582914?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:45","pubTimestamp":1788950714,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share repurchase cancellation at HKD 20.82-21.38Zylox-Tonbridge filed a next-day disclosure return reporting an on-market buyback of 53,500 H s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL3Z32VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02190","BK1100","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143782105","title":"UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick","url":"https://stock-news.laohu8.com/highlight/detail?id=1143782105","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143782105?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:03","pubTimestamp":1788940980,"startTime":"0","endTime":"0","summary":"UBS has released a research report indicating that first-half results among Chinese pharmaceutical stocks were mixed, with five of the nine rated companies exceeding market expectations. These...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","HK0000165453.HKD","BK1521","IE00BZ08YT58.USD","BK1589","IE00B3M56506.USD","01177","02096","BK1191","IE00BZ08YR35.GBP","BK1593","BK1583","BK1161","01530","BK1515","BK1574","03933","01477","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144997108","title":"Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=1144997108","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144997108?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:00","pubTimestamp":1788940815,"startTime":"0","endTime":"0","summary":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","688192","159938","09939","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112577285","title":"BOC International sees pharma sector earnings recovery as industry enters a reversal cycle","url":"https://stock-news.laohu8.com/highlight/detail?id=1112577285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112577285?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:30","pubTimestamp":1788924637,"startTime":"0","endTime":"0","summary":"The pharmaceutical sector's interim reports for the first half of 2026 have been fully released, revealing resilient overall growth with structural improvements continuing to unfold, according to BOC...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159200143","title":"HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1159200143","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159200143?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:30","pubTimestamp":1788924624,"startTime":"0","endTime":"0","summary":"VIVA BIOTECH (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.According to the company's recently disclosed first-half...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1141","KCAI","01873","BK4585","BK1574","CDMO","VXUS","BK1191","BK4588","BK4139","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666033309","title":"HK-Listed HBM Climbs on Initiating Next Phase of Asthma Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666033309","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666033309?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:47","pubTimestamp":1788922062,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed HBM climbs on initiating next phase of asthma drug study** Shares of HBM Holdings2142.HKclimb 3.7% to HK$15.09** Therapeutics developer says its partner Windward Bio AG reportedpositive","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL1N45102M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141984241","title":"Hong Kong Stock Market Movers: HBM Holdings-B (02142) Climbs Over 4% in Morning Session After Positive Asthma Trial Results and Stock Connect Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1141984241","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141984241?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:42","pubTimestamp":1788921769,"startTime":"0","endTime":"0","summary":"Shares of HBM Holdings-B (02142) surged more than 4% during Tuesday's morning trading session, with the stock last changing hands at HK$15.23, up 4.67%, on turnover of approximately HK$59.8...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1583","BK1161","BK1574","BK4588","KCAI","02142","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309337","title":"Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309337","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309337?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:03","pubTimestamp":1788919398,"startTime":"0","endTime":"0","summary":"BUZZ-Ascletis hits 4-week high on initiating US Phase I study on obesity drug** Shares of Ascletis Pharma Inc1672.HKclimb 5.6% to HK$10.75, their highest since August 13** Stock on track for biggest one-day pct gain since August 7** Pharmaceutical products producer says it hasinitiateda U.S. Phase I study of ASC36 oral tablets for treatment of obesity after receiving Investigational New Drug clearance from the U.S. Food and Drug Administration** ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in non-human primates - co** YTD, stock down 7.3%, while Hang Seng Biotech Index.HSBIOup 10.7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL1N451020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186275720","title":"How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1186275720","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186275720?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:41","pubTimestamp":1788910867,"startTime":"0","endTime":"0","summary":"Traditional Chinese Medicine (TCM) has long been built on the accumulated wisdom of generations of physicians. However, when measured against the rigorous standards of modern medicine, the industry...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4159","BK1161","MEDX","LNGR","IBBQ","06978","RCT","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136667600","title":"TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1136667600","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136667600?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:26","pubTimestamp":1788873985,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) has announced that its Chairman, Executive Director and President, Dr. Wu Yusheng, has informed the company of his recent share purchases in the open market. Dr. Wu may...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","09939","BK1574","BK1515","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167922243","title":"HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III","url":"https://stock-news.laohu8.com/highlight/detail?id=1167922243","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167922243?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:58","pubTimestamp":1788872333,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) has announced that its partner, Windward Bio AG, has reported positive interim results from the Phase II portion of the POLARIS-1 clinical trial evaluating HBM9378/WIN378 for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154956841","title":"Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1154956841","media":"Deep News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154956841?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:52","pubTimestamp":1788871964,"startTime":"0","endTime":"0","summary":"Chengdu Easton Biopharmaceuticals Co.,Ltd. (SSE: 688513) announced on September 8 that it will take part in the Science and Technology Innovation Board's collective earnings briefing for the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","159992","688513","MEDX","IBBQ","BK1161","KSTR","LNGR","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320273","title":"HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320273","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320273?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869907,"startTime":"0","endTime":"0","summary":"HBM says partner Windward Bio starts Phase 3 asthma trial of twice-yearly TSLP antibody HBM9378/WIN378HBM Holdings highlighted positive interim Phase 2 asthma results for HBM9378/WIN378, an ultra-long","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4WknG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320213","title":"Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320213?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:17","pubTimestamp":1788869848,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA60HVBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":7,"totalSize":220,"code":"91000000","status":"200"}]}}